BFA
AZN icon

BMS Financial Advisors’s AstraZeneca AZN Stock Holding History

BMS Financial Advisors’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$400K Sell
2,793
-1,143
-29% -$168K 0.26% 69
2023
Q1 		$546K Buy
+3,936
New +$530K 0.38% 59

Other funds holding AZN

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
GQG Partners
GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BMS Financial Advisors's AZN Position: Q2 2023 in Review

BMS Financial Advisors reduced its AstraZeneca (AZN) stake by 29% in Q2 2023, selling an estimated $168K and leaving 2,793 shares worth $400K. The position accounts for 0.26% of the portfolio, ranked #69.

BMS Financial Advisors first reported a position in AZN in Q1 2023 and has held it in 2 quarters since. The position peaked at $546K in Q1 2023. 1,091 funds tracked by Wall St. Rank hold AZN as of Q2 2023.

  • BMS Financial Advisors held 2,793 shares of AstraZeneca worth $400K as of Q2 2023.
  • BMS Financial Advisors sold 1,143 AstraZeneca shares in Q2 2023, an estimated $168K.
  • AstraZeneca made up 0.26% of BMS Financial Advisors's portfolio in Q2 2023, its #69 holding.
  • BMS Financial Advisors first reported a position in AstraZeneca in Q1 2023 and has held it in 2 quarters since.
  • BMS Financial Advisors's AstraZeneca position peaked at $546K in Q1 2023.
  • 1,091 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2023.

Based on BMS Financial Advisors's 13F filing for Q2 2023, filed 31 Jul 2023.